This week a laboratory that built its name on finding contaminants the regulators missed sued the organization that sets quality standards for American medicines. Valisure, of New Haven, Connecticut, filed suit on August 13 in federal court in Connecticut against the U.S. Pharmacopeial Convention, the independent body known as USP whose standards underpin how drugs are tested and certified. According to STAT's Pharmalot column, the complaint, brought under the Lanham Act and demanding a jury, alleges that USP published "false and misleading remarks" about the lab's methods in a 2023 white paper, portraying the lab as relying on tests that had never been validated, producing results the standards body called misleading and causing public concern the science did not justify, all to defend a standards system from which USP earns money. The docket entry shows the case assigned to the District of Connecticut.
The technical dispute beneath all of this is real and complicated, a fair question for a court: how a laboratory proves that its tests say what they claim to say, and what happens to public confidence when competing answers are on offer. But there is a layer underneath it that the headlines skip. Neither Valisure nor USP sells pills. What each one sells is a claim about medicines, and the value of that claim is entirely a function of whether anyone believes it. The lawsuit is a boundary fight over that belief: who gets to speak about drug safety, and whose word counts. This analysis takes no position on the merits of the litigation or on the science; it is an attempt to read what the fight is really for.
Neither institution sells what it appears to sell
USP develops public standards for medicines, publishes reference materials, and works with regulators and manufacturers around the world. Its name on a standard is a certificate of a sort: it tells a manufacturer what to make, a pharmacist what to verify, and a patient that the product in the bottle meets a published bar. That authority is the asset. If the public stops believing a USP standard means something dependable, the institution shrinks to a publisher of documents nobody heeds.
Valisure is the mirror image, and its history makes the point concrete. It sells findings: an alert that a heartburn drug breaks down into a probable carcinogen, that a sunscreen contains benzene, that a dry shampoo is contaminated. A finding nobody believes is worthless, and a lab that cries wolf loses the only thing it has: the standing to be believed next time. Both live and die on credibility, which is another way of saying both are in the trust business.
The white paper was an argument about trust, not chemistry
The document at the center of the case is USP's 2023 white paper, "Unvalidated methods for medicine quality testing lead to misleading results." Its argument, in brief: only validated analytical methods can reliably assess a medicine's quality, and unvalidated methods frequently mislead, raising concern that can panic patients, alter prescribing, and contribute to shortages. The paper discusses Valisure's testing, citing an FDA inspection and a 2022 agency letter describing methodological deficiencies, including failures to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods, and noting that FDA scientists found Valisure's technique could itself create the impurity it was hunting for.
STAT's earlier reporting on that letter records Valisure's reply at the time: its testing was meant for informational and marketing purposes, not for regulation, a position the agency rejected because others were relying on the results as though they were regulatory-grade. The letter is not a scientific verdict, but it is the strongest public document on USP's side, and the white paper leans on it. Valisure's complaint, in turn, reads the white paper as a market play: an institution with a stake in its own standards using its authority to disqualify a rival's testing in the eyes of the public.
Standards trust and sentinel trust
The two institutions represent two ways a society assures itself that medicines are what they claim to be. The standards model is slow, careful, institutional, built on validated methods, consensus, and documentation. The sentinel model is fast, aggressive, detection-first: a small lab scanning the shelves for what the system missed. Each has a failure mode that looks exactly like the other's virtue. The standards model is slow to move at all, and from the sentinel's vantage that caution looks like suppression: the FDA took months to act on ranitidine after Valisure raised the alarm. The sentinel model is fast to be wrong, and from the standards side that speed looks like recklessness: an unvalidated method that manufactures the contaminant it reports is worse than no method at all.
Both failure modes carry real costs, and each side's failure falls mostly on the other institution. A false alarm empties a shelf of a medicine people need; the standards bodies and manufacturers pay for it in lost trust and lost product. False reassurance leaves a carcinogen on the shelf; the sentinels, who built their reputations on the premise that the system misses things, pay in the accusation that they missed it too. Each side therefore polices the other, and this lawsuit is a formal installment of that policing, conducted with lawyers instead of press releases.
Why the law is the arena
The choice of a Lanham Act claim is telling. That statute governs false advertising and unfair competition, and it exists because reputation is a marketable asset that disparagement can damage as surely as fire can damage a warehouse. For the claim to work, Valisure must show that USP's words injured its market position, and the complaint tells that story in commercial terms: a standards body with revenue tied to its own system using its pulpit against a competitor. Valisure is not asking the court to certify its chemistry; it is asking it to find that USP's words cost the lab business, and for Valisure, business means being believed. The legal fight is therefore a contest over the trust franchise, with the allegations in the complaint unproven and denied.
None of this is a criticism of either party. Reputation disputes belong in courts, and a claim that a rival's words damaged your market is an ordinary commercial grievance. The revealing part is the choice of forum: the parties understand that the asset at stake is not the chemistry but the belief, which the evidence of market harm will be about. Whatever the outcome, a court will adjudicate who may speak for drug quality and what the consequences of speaking are: the courtroom's ordinary job when the product is trust.
The record that made this fight possible
Consider the record. Valisure's findings have repeatedly preceded official action. It was the first to report that ranitidine, sold as Zantac and in generics, could form the probable carcinogen NDMA, which eventually led regulators to pull the products from the market. Its benzene findings in hand sanitizers, sunscreens, body sprays, and dry shampoos led to recalls of tens of millions of products. Supporters, including Rep. Rosa DeLauro of Connecticut, have accused regulators and industry of shooting the messenger, and Consumer Reports has documented how manufacturers used the FDA's inspection findings to undermine the lab's claims.
The other side of that record is equally substantial. A federal judge dismissed the mass ranitidine litigation after finding the plaintiffs' expert evidence did not hold up, and the drugmakers eventually settled most of the remaining state claims for billions without admitting the science. Critics have gone further, describing a lab whose testing has fueled a litigation industry on evidence the courts rejected. Both stories are true of the same institution, which is why who gets believed is so consequential: the answer decides which version of the record governs the next alert, the next recall, the next headline.
The trust that neither party can manufacture
The part neither the lawsuit nor the white paper can address: the trust being fought over belongs to the public, and it is the one asset in this fight that neither party can manufacture, verify, or insure. A lab cannot buy belief in its alerts; a standards body cannot legislate belief in its standards. Both accumulate credibility by being right and lose it in a single episode of being wrong. The system works because each institution's self-interest forces it to check the other: Valisure profits when its alarms prove real, USP profits when its standards hold up, and the public benefits from their mutual suspicion. The danger would be a world in which only one of them was believed, because then the auditing would stop.
Read that way, the lawsuit is not a breakdown of the system; it is the system being honest about its shape: two trust franchises in a permanent contest over the same audience, asking the courts to draw the boundary between them. However the boundary is drawn, the underlying condition remains: somebody has to say whether a medicine is safe, and the people who say it are only as strong as the belief they have earned. Patients are left with a practical question no verdict will fully settle: how much weight to give a warning from a lab with this record, and how much to give a standard from an institution with its own. The honest answer is that both should be examined, in public, which is what this fight is forcing everyone to do.
Primary sources
- STAT's Pharmalot column, reporting by Ed Silverman, for the report of Valisure's lawsuit against USP, the nature of the claims, and Valisure's allegations about the 2023 white paper, and the Justia docket for Valisure, LLC v. United States Pharmacopeial Convention for the case number, court, filing date, and Lanham Act claim.
- The USP white paper itself for USP's arguments about unvalidated methods, misleading results, and unnecessary concern, and for its references to the FDA's inspection and letter, and STAT's earlier Pharmalot reporting for the FDA's December 2022 untitled letter to Valisure and its description of methodological deficiencies.
- Consumer Reports for the FDA's inspection of Valisure, the scale of the recalls its findings produced, and manufacturers' use of the inspection findings against the lab.
- The BMJ for the settlement of most U.S. ranitidine lawsuits and the resolution of Valisure's whistleblower suit, and The Hill's commentary for the criticism that Valisure's testing has fueled litigation.